Cargando…
Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy
INTRODUCTION: Chimeric antigen receptor T-cell (CAR-T) therapy is a class of immunotherapy. An economic evaluation conducted at an early stage of development of CAR-T therapy for treatment of adult relapsed or refractory acute lymphoblastic leukaemia could provide insight into factors contributing t...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362692/ https://www.ncbi.nlm.nih.gov/pubmed/34385243 http://dx.doi.org/10.1136/bmjopen-2020-046707 |
_version_ | 1783738217416097792 |
---|---|
author | Wilson, Mackenzie Thavorn, Kednapa Hawrysh, Terry Graham, Ian D Atkins, Harold Kekre, Natasha Coyle, Doug Lalu, Manoj M Fergusson, Dean A Chan, Kelvin KW Ollendorf, Daniel A Presseau, Justin |
author_facet | Wilson, Mackenzie Thavorn, Kednapa Hawrysh, Terry Graham, Ian D Atkins, Harold Kekre, Natasha Coyle, Doug Lalu, Manoj M Fergusson, Dean A Chan, Kelvin KW Ollendorf, Daniel A Presseau, Justin |
author_sort | Wilson, Mackenzie |
collection | PubMed |
description | INTRODUCTION: Chimeric antigen receptor T-cell (CAR-T) therapy is a class of immunotherapy. An economic evaluation conducted at an early stage of development of CAR-T therapy for treatment of adult relapsed or refractory acute lymphoblastic leukaemia could provide insight into factors contributing to the cost of treatment, the potential clinical benefits, and what the health system can afford. Traditionally, stakeholders are engaged in certain parts of health technology assessment processes, such as in the identification and selection of technologies, formulation of recommendations, and implementation of recommendations; however, little is known about processes for stakeholder engagement during the conduct of the assessment. This is especially the case for economic evaluations. Stakeholders, such as clinicians, policy-makers, patients, and their support networks, have insight into factors that can enhance the validity of an economic evaluation model. This research outlines a specific methodology for stakeholder engagement and represents an avenue to enhance health economic evaluations and support the use of these models to inform decision making for resource allocation. This protocol may inform a tailored framework for stakeholder engagement processes in future economic evaluation model development. METHODS AND ANALYSIS: We will involve clinicians, healthcare researchers, payers, and policy-makers, as well as patients and their support networks in the conduct and verification of an early economic evaluation of a novel health technology to incorporate stakeholder-generated knowledge. Three stakeholder-specific focus groups will be conducted using an online adaptation of the nominal group technique to elicit considerations from each. This study will use CAR-T therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia as a basis for investigating broader stakeholder engagement processes. ETHICS AND DISSEMINATION: This study received ethics approval from the Ottawa Hospital Research Institute Research Ethics Board (REB 20200320-01HT) and the results will be shared via conference presentations, peer-reviewed publications, and ongoing stakeholder engagement. |
format | Online Article Text |
id | pubmed-8362692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-83626922021-08-30 Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy Wilson, Mackenzie Thavorn, Kednapa Hawrysh, Terry Graham, Ian D Atkins, Harold Kekre, Natasha Coyle, Doug Lalu, Manoj M Fergusson, Dean A Chan, Kelvin KW Ollendorf, Daniel A Presseau, Justin BMJ Open Health Economics INTRODUCTION: Chimeric antigen receptor T-cell (CAR-T) therapy is a class of immunotherapy. An economic evaluation conducted at an early stage of development of CAR-T therapy for treatment of adult relapsed or refractory acute lymphoblastic leukaemia could provide insight into factors contributing to the cost of treatment, the potential clinical benefits, and what the health system can afford. Traditionally, stakeholders are engaged in certain parts of health technology assessment processes, such as in the identification and selection of technologies, formulation of recommendations, and implementation of recommendations; however, little is known about processes for stakeholder engagement during the conduct of the assessment. This is especially the case for economic evaluations. Stakeholders, such as clinicians, policy-makers, patients, and their support networks, have insight into factors that can enhance the validity of an economic evaluation model. This research outlines a specific methodology for stakeholder engagement and represents an avenue to enhance health economic evaluations and support the use of these models to inform decision making for resource allocation. This protocol may inform a tailored framework for stakeholder engagement processes in future economic evaluation model development. METHODS AND ANALYSIS: We will involve clinicians, healthcare researchers, payers, and policy-makers, as well as patients and their support networks in the conduct and verification of an early economic evaluation of a novel health technology to incorporate stakeholder-generated knowledge. Three stakeholder-specific focus groups will be conducted using an online adaptation of the nominal group technique to elicit considerations from each. This study will use CAR-T therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia as a basis for investigating broader stakeholder engagement processes. ETHICS AND DISSEMINATION: This study received ethics approval from the Ottawa Hospital Research Institute Research Ethics Board (REB 20200320-01HT) and the results will be shared via conference presentations, peer-reviewed publications, and ongoing stakeholder engagement. BMJ Publishing Group 2021-08-12 /pmc/articles/PMC8362692/ /pubmed/34385243 http://dx.doi.org/10.1136/bmjopen-2020-046707 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Health Economics Wilson, Mackenzie Thavorn, Kednapa Hawrysh, Terry Graham, Ian D Atkins, Harold Kekre, Natasha Coyle, Doug Lalu, Manoj M Fergusson, Dean A Chan, Kelvin KW Ollendorf, Daniel A Presseau, Justin Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy |
title | Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy |
title_full | Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy |
title_fullStr | Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy |
title_full_unstemmed | Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy |
title_short | Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy |
title_sort | stakeholder engagement in economic evaluation: protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor t-cell therapy |
topic | Health Economics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362692/ https://www.ncbi.nlm.nih.gov/pubmed/34385243 http://dx.doi.org/10.1136/bmjopen-2020-046707 |
work_keys_str_mv | AT wilsonmackenzie stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT thavornkednapa stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT hawryshterry stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT grahamiand stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT atkinsharold stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT kekrenatasha stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT coyledoug stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT lalumanojm stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT fergussondeana stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT chankelvinkw stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT ollendorfdaniela stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy AT presseaujustin stakeholderengagementineconomicevaluationprotocolforusingthenominalgrouptechniquetoelicitpatienthealthcareproviderandhealthsystemstakeholderinputinthedevelopmentofanearlyeconomicevaluationmodelofchimericantigenreceptortcelltherapy |